Revance, a topical form of Botox, is looking promising during trials.
Dr. Joel Schlessinger reports that Revance, a topical form of Botox, is poised to enter phase 3 trials.
The doctor reported this exciting news at the annual meeting of the American Academy of Cosmetic Surgery‘s annual meeting early in 2011. At this meeting, Joel Schlessinger also announced that it will take time for these trials to be underway. His announcement was covered in the January 14, 2011 post of New You, titled “Going Needle-Free.”
According to a press release by the manufacturers of Revance, the initial study consisted of 90 subjects and both the investigator and the patient rated the success of the procedure. Success was defined by a pre-determined level of reduction in wrinkle severity. Results were quite promising. The second phase of the study had 180 participants, with equally promising results.
A topical form of Botox will be especially helpful for people who don’t want needles injected in their face – and for those who are actually needle phobic.
It wasn’t until 1997 that medical health professionals added needle phobia (officially called “belonephobia”) to the Diagnostic and Statistical Manual of Mental Disorders. This is largely because of research conducted by family practitioner, Dr. James Hamilton.
Now, experts estimate that needle phobia may affect up to 10% of people – and it’s possible that this phobia can be inherited; this research was reported on by ABC News and other large news organizations.
Watch this blog for more updates about Revance and other important news by Dr. Joel Schlessinger.
Freelance writers, editors, journalist and bloggers: are you looking for an expert for your article? Contact Dr. Joel Schlessinger today.